Primary or AL amyloidosis results from a plasma cell dyscrasia in which fibrillar light chain protein deposition leads to organ failure and death. Standard treatment for AL amyloidosis has been oral melphalan and prednisone. However, this form of treatment modifies the natural history of this lethal disease only marginally, extending median survival from 13 months following diagnosis to 17 months. At Boston University Medical Center, we have developed treatment protocols using high-dose intravenous melphalan with autologous peripheral blood stem cell transplantation (HDM/SCT) to treat AL amyloidosis, and we have treated over 200 patients with HDM/SCT during the past six years. This extensive experience has shown that patients with AL amyloidosis, despite multisystem involvement and compromised organ function can tolerate this aggressive form of treatment. Furthermore, HDM/SCT results in durable hematologic responses in a substantial proportion of patients, and such responses are associated with clinical improvement, decreased amyloid-related organ dysfunction, and prolonged survival. However, toxicity from treatment is high (overall peri-transplant mortality, 14%), particularly for those patients with clinically significant cardiac involvement. For this reason, we believe a multidisciplinary management approach is essential when using HDM/SCT for treatment of AL amyloidosis. Based on our experience, we believe that HDM/SCT is the treatment of choice for patients with AL amyloidosis who have a good performance status and limited cardiac involvement at the time of diagnosis. HDM/SCT offers the best chance for hematologic remission, prolongation of survival, and reversal of amyloid-related disease. At the same time, we believe that HDM/SCT should continue to be examined in the context of clinical trials, directed at developing approaches to broaden the applicability of this therapy by minimizing toxicity and to increase the likelihood of 
Systemic amyloidosis is a multisystem disease caused by widespread, pathologic, extracellular deposition of insoluble fibrillar proteins in organs and tissues. The process by which precursor proteins produce fibrils is multifactorial and differs among the various types of amyloid. 1 Primary or 'AL' amyloidosis is the most common and arguably the most aggressive and lethal form of systemic amyloidosis. In this disorder, amyloid protein deposits are derived from monoclonal immunoglobulin light chains secreted by neoplastic plasma cell clones. Although the burden of clonal plasma cells in AL amyloidosis is generally low, the accumulation of amyloid deposits in the heart, kidneys, liver, GI tract and autonomic nervous system leads to progressive disability, organ failure and death. The median survival of untreated patients is 13 months from the time of diagnosis, 2 with a considerably worse median survival of 4 months for patients with congestive heart failure at diagnosis. Although long-term survival of untreated patients with AL amyloidosis (eg more than 10 years from diagnosis) can occur, such indolent progression of disease is rare (Ͻ5%). 3 Several prospective, randomized clinical trials have shown that cyclic, low-dose oral melphalan and prednisone is beneficial, increasing the median survival of patients to about 17 months. 4, 5 However, cyclic oral melphalan only rarely results in complete hematologic responses (eg elimination of the underlying plasma cell dyscrasia) or in reversal of amyloid-related organ dysfunction. Combination chemotherapy with VBMCP (vincristine, carmustine, melphalan, cyclophosphamide and prednisone) has also been studied in a randomized, prospective fashion in this disorder but was found not to improve response rates or survival. 6 Initial pilot studies of high-dose chemotherapy and blood stem cell transplantation for the treatment of AL amyloidosis High-dose intravenous melphalan chemotherapy and autologous peripheral blood stem cell transplantation has been successful in inducing complete hematologic remissions and prolonging survival in multiple myeloma. 7 Therefore, it was logical to apply this approach to the treatment of AL amyloidosis.
The Amyloid Research and Treatment Program at Boston University School of Medicine has had a long-standing investigative interest in the pathophysiology and treatment of the various forms of systemic amyloidosis. In 1994, a multidisciplinary clinical group was formed at Boston University Medical Center to develop high-dose chemotherapy protocols for AL amyloidosis. This group was made up of clinicians allied with the Amyloid Research and Treatment Program, representing the disciplines of cardiology, nephrology, pulmonology, neurology, gastroenterology and rheumatology, together with hematologists in the Stem Cell Transplant Program of the Section of Hematology and Oncology.
We reported our initial experience with high-dose melphalan and stem cell transplantation (HDM/SCT) in five patients with AL amyloidosis in 1996. 8 This pilot study showed that AL amyloidosis patients with significant systemic disease could be successfully treated with dose-intensive chemotherapy. Furthermore, three of the five patients achieved a complete hematologic response, with disappearance of their underlying clonal plasma cell disorder following treatment. Moreover, all five patients experienced reversal of amyloid-related organ dysfunction.
An expanded series of 25 patients was reported in 1998. 9 Among these 25 patients, hematologic complete responses were observed in 13 of 21 evaluable patients (62%), and 65% experienced improvement in amyloid-related organ dysfunction.
Cumulative 6 year experience with high-dose chemotherapy and blood stem cell transplantation at Boston University Medical Center
We have now treated over 200 patients with AL amyloidosis with HDM/SCT. 10 The details of this series are being reported elsewhere. Although patients have been treated on a number of separate protocols during the past 6 years, all protocols have shared common eligibility criteria and treatment elements. In all cases, we have required a confirmed tissue diagnosis of amyloidosis, clear evidence of a clonal plasma cell dyscrasia, age Ͼ18 years, and minimum measures of performance status (SWOG 0-2), cardiac function (LVEF Ͼ40%), pulmonary function (O 2 saturation у95% on room air), and hemodynamic stability (baseline systolic blood pressure у90 mm Hg). Patients on hemodialysis or peritoneal dialysis for renal failure were not excluded if other eligibility criteria were met. There was also no set upper age limit.
Between June 1994 and April 2000, 205 patients with AL amyloidosis began high-dose melphalan treatment protocols. Twenty of these patients began stem cell mobilization and collection but did not proceed to high-dose chemotherapy and transplant, either because of death (six patients) or complications (14 patients) during the initial phase of treatment. Of the 185 patients who completed chemotherapy and transplant, there were 22 deaths within 3 months of treatment. This early mortality of 14% (28/205) reflects the clinical fragility of this patient population, particularly those with evidence of amyloid cardiomyopathy who accounted for 70% (20/28) of the early deaths.
One hundred and fifty-two patients completed high-dose melphalan and transplant prior to April 1999, for whom there was the possibility of at least 1 year of follow up by April 2000. The median age of these 152 patients was 56 (range 29-80), with a male:female ratio of 1.5:1.0. Seventyseven of these patients received full high-dose melphalan (200 mg/m 2 ) and 75 received modified high-dose treatment (100-140 mg/m 2 ). Of these 152 patients, 115 (76%) survived for at least 1 year following treatment and were evaluated for hematologic and clinical responses. Hematologic CR was defined as absence of a monoclonal protein in serum and urine by immunofixation electrophoresis together with a bone marrow biopsy showing less than 5% plasma cells without clonal dominance of or light chain isotypes. Fortyseven percent (54/115) of patients evaluated at 1 year after treatment were found to be in hematologic CR. Patients who received 200 mg/m 2 of melphalan were more likely to have a hematologic CR at 1 year (56%), than were those who received modified high-dose melphalan (35%) (P = 0.04). Furthermore, hematologic CRs have proven to be durable. Of the 54 patients with a hematologic CR at 1 year, only three to date have relapsed with reappearance of their clonal plasma cell disorder; two patients relapsing at 2 years and the third at 3 years.
Median survival for the entire group of 152 patients treated prior to April 1999 has not as yet been reached (Table 1) . Survival was influenced significantly by whether or not hematologic CR was evident at 1 year following treatment. Survival was also clearly influenced by whether or not patients had evidence of amyloid cardiomyopathy by ECHO or EKG at the time of treatment. The influence of cardiac involvement on survival was apparent both for patients who achieved hematologic CR and for those who did not.
Amyloid-related organ response was also determined 1 year following treatment. Response criteria were defined as follows: renal, a 50% reduction in proteinuria without deterioration in glomerular filtration rate; 11 liver, a 50% reduction in alkaline phosphatase and/or reduction in liver span of at least 2 cm; cardiac, echocardiographic stabilization of cardiac disease (Ͻ2 mm increase in the wall thickness and/or 20 g increase in left ventricle mass); factor X deficiency, normalization of factor X levels. 12 Improvements in all categories of organ involvement were observed as summarized in Table 2 . In addition, most patients with autonomic and peripheral neuropathies experienced dramatic clinical improvements, although this has not been quantified. Such responses were observed in both the hematologic CR and non-CR groups.
Special problems of chemotherapy and transplant in AL amyloidosis
Patients with AL amyloidosis typically have organ impairment that predisposes them to increased peri-transplant morbidity and mortality. Table 3 shows the frequency of grade Ͼ2 toxicities (NCI Common Toxicity Criteria) encountered in our group of patients. Unique clinical challenges with AL amyloidosis patients that warrant special mention relate to the management of nutrition, macroglossia, orthostatic hypotension, volume status and cardiac arrhythmias.
Pretransplant assessment of gastrointestinal function and mucosal integrity has been essential. We have found that such assessment appropriately includes a detailed review of gastrointestinal signs and symptoms, serial stool exams for occult blood loss, endoscopic studies to define pathology if indicated, and a complete assessment of coagulation status. Patients with poor nutrition because of gastrointestinal dysfunction and dysmotility, anorexia, or dysgeusia have gen- Table 3 Frequency of grade Ͼ2 toxicity Bone Marrow Transplantation erally required oral or parenteral nutrition supplements in the pre-and post-transplant period. Nephrotic syndrome associated with renal amyloidosis has been observed not uncommonly to lead to severe hypoalbuminemia and edema or anasarca. We have found that albumin infusions to raise the serum albumin to greater than 1.5 g/dl followed by loop diuretics have been effective in managing these complications.
Hypoalbuminemia, autonomic insufficiency, hypoadrenalsim, and cardiac disease can lead to severe orthostatic hypotension in these patients. Thigh-high stockings, midodrine and fludrocortisone have proven useful in managing these problems.
Cardiac disease has been observed to predispose patients to atrial and ventricular arrhythmias as well as to symptoms and signs of restrictive cardiomyopathy. Management of such patients in coordination with an experienced cardiologist has proven to be critical. Amiodarone is often an effective anti-arrhythmic, while beta blockers, calcium channel blockers, and digoxin have often been poorly tolerated by these patients.
Deficiency of factor X, along with the poor endothelial and connective tissue integrity from amyloid deposition, is associated with an increased risk of cutaneous and mucosal bleeding, including disease-specific raccoon eye ecchymoses. Patients with factor X deficiency are at particularly high risk of bleeding complications during periods of thrombocytopenia. Hence, we have found that screening for factor X deficiency must be done prior to treatment. This issue has been discussed in detail in a recent publication. 12 Additional unusual problems that may be encountered in these patients include difficulties with emergent endotracheal intubation in patients with macroglossia, spontaneous splenic and esophageal rupture, and hypercoagulability in association with nephrotic syndrome.
Patient selection
Patients who have received high-dose chemotherapy and stem cell transplantation in our phase I and II clinical trials represent a selected patient group. A retrospective review of the amyloid database from June 1994 to September 1999 at Boston University indicates that 39% of patients with a new diagnosis of AL amyloidosis were considered to be ineligible for treatment on clinical trials of HDM/SCT due to poor performance status, severe cardiac involvement, or multisystem organ failure. Sixteen percent did not pursue treatment because of non-medical reasons. However, 45% of patients were offered treatment, including patients of advanced age, on dialysis, and with evidence of cardiac disease.
Age Ͼ65 years
Twenty-seven patients over the age of 65 were treated with intravenous melphalan at 100-200 mg/m 2 with stem cell rescue. Two of 27 patients (7%) died due to peri-transplant toxicities within 3 months. Fifty-eight percent (11/19) of the surviving patients achieved a hematologic CR; 70% sur-vived for at least 1 year. These results are as favorable, if not more favorable, than those for our entire treatment cohort. Thus, we find that HDM/SCT is tolerable and effective treatment for selected older patients.
Patients on dialysis
Patients on hemodialysis or peritoneal dialysis for end stage renal disease (ESRD) were not excluded from our treatment protocols, if they met other eligibility criteria. We have treated 12 patients with AL amyloidosis-associated ESRD with intravenous melphalan 100-200 mg/m 2 . The outcomes of these patients will be reported in detail in a separate manuscript. Although some treatment-related toxicities occurred more frequently in these patients, the CR rate and 1 year survival rate did not differ between the ESRD and non-ESRD patients. Based on our experience, we believe that ESRD, in and of itself, is not a contraindication to HDM/SCT.
Cardiac disease
A thickened ventricular septum has been proposed as an absolute contraindication to high-dose chemotherapy and transplantation. 13, 14 We have treated 26 high-risk patients with an interventricular septum thickness of у15 mm. Of these, 14 patients have died, five (14%) in the peritransplant setting and eight (31%) within 1 year of treatment. However, 46% (12/26) patients have survived with follow-up of 26-66 months. The median survival for this group is slightly less than 2 years, with 64% surviving for 1 year, 49% for 2 years and 40% for 3 years. This compares very favorably with the survival of patients with cardiac disease treated with oral melphalan and prednisone, 4 for whom median survival was 5 months, and survival at 1, 2 and 3 years was 35%, 23% and 21%, respectively. Thus, our experience suggests that septal thickness alone does not assure a poor outcome. At the same time we continue to believe that, patients with New York Heart Association classification class III or class IV congestive heart failure, left ventricular ejection fraction of less than 40%, symptomatic ventricular tachycardia, exertional syncope and thromboembolic events from atrial dysfunction are at such high risk of developing lethal complications during HDM/SCT that this form of treatment is inappropriate for them.
Experience with high-dose chemotherapy and stem cell transplantation at other centers
Other centers have carried out pilot studies of high-dose chemotherapy and stem cell transplantation for AL amyloidosis with varying results. Reported experience is shown in Table 4 .
The Mayo Clinic recently reported their experience with 23 patients entered on to treatment protocols from November 1995 to September 1998. 13 Their stem cell mobilization regimen included a combination of cyclophosphamide (3 g/m 2 ) and growth factor; three patients did not proceed with treatment because of complications of mobilization.
Conditioning was carried out with either melphalan and TBI or melphalan alone. Four of 20 patients (20%) died as a result of treatment-related mortality. Twelve of 20 patients (60%) fulfilled criteria for hematologic or organ response. Thirteen patients survived with a follow-up of 3 to 26 months.
Moreau et al 15 recently reported on a multicenter study of 21 patients. They found an unexpectedly high treatmentrelated mortality rate of 43% (nine of 21), but 10 of the 12 survivors (83%) achieved a response. Their conditioning regimen also consisted of high-dose melphalan alone or with total body irradiation (TBI).
Gillmore et al 16 also reported, in abstract form, 40 patients who underwent high-dose melphalan therapy, with 37% treatment-related deaths. However, a clinical response was seen in 53% of patients.
Current recommendations and future directions
Our data and that from other centers indicate that, despite multisystem organ dysfunction, patients with AL amyloidosis can tolerate high-dose melphalan and autologous stem cell transplantation. Moreover, dose-intensive chemotherapy can induce complete hematologic responses in a substantial proportion of patients who complete treatment. Furthermore, complete hematologic responses in AL amyloidosis are associated with reversal of amyloid-related organ dysfunction and may lead to prolonged survival in this disease, which is typically fatal within 2 years when managed with standard oral chemotherapy regimens. We believe that a number of lessons can be learned from our experience and from that of others, with regard to the use of HDM/SCT in the treatment of AL amyloidosis.
Multidisciplinary patient management
Over the past 6 years, we have treated a large number of AL amyloidosis patients with HDM/SCT including patients over 65, patients on dialysis, and patients with cardiac disease. While patient selection remains important in achieving an acceptable outcome, we also believe that the relatively low treatment-related mortality that we have observed, compared to that reported by others, is in part attributable to the multidisciplinary approach to patient management carried out at our institution. Each patient is evaluated by a team of subspecialists who are familiar with the manifestations and treatment of amyloidosis. These subspecialists remain available to the transplant physicians throughout therapy, and the amyloid clinical team meets regularly to review each patient's progress during treatment. We encourage other transplant centers undertaking treatment of these complicated patients to adopt a similar multidisciplinary management approach.
Stem cell mobilization
Stem cell mobilization has unusually high morbidity for these patients, because of their propensity for fluid retention, edema, pleural effusions, hypoxemia, and severe hypotension. At present, we believe that stem cell mobili-641 Table 4 Reported experience of HDM/SCT Table 2 .
zation with G-CSF alone is the best approach. We have treated seven patients with a combination of cyclophosphamide (2.5-4.0 g/m 2 ) along with growth factor for stem cell mobilization; three of these patients experienced fatal complications. The Mayo Clinic has also reported morbidity associated with cyclophosphamide and growth factor mobilization regimens. Currently, we employ G-CSF 16 g/kg/day given in a single dose or in two divided doses for 3 days for stem cell mobilization.
Conditioning
Conditioning regimens for multiple myeloma have employed either melphalan alone or melphalan with TBI, with similar outcomes. However, there has been a suggestion of more toxicity with the addition of TBI. The Mayo Clinic observed a higher incidence of mucositis as well as an increased need for total parenteral nutrition in patients receiving total body irradiation. 13 In a series of 10 patients, a higher risk of cardiorespiratory events was attributed to the use of TBI. 17 Throughout, we have used melphalan alone for conditioning, with dose modifications for patients older than 65 or with diminished cardiac function. However, as described above, hematologic responses appear to be dose-dependent. Future studies may explore the use of other chemotherapy agents in combination with melphalan to improve complete hematologic remission rates.
Future trials
In the past, AL amyloidosis was a uniformly progressive and fatal disease, with long-term survival being a rare outcome with oral melphalan and prednisone treatment. Development of peripheral blood stem cell transplantation with growth factor support has allowed for more aggressive treatment of these patients and, as reviewed above, HDM/SCT can result in durable complete remissions and major improvements in organ function. Efforts in the future should focus on improving supportive care to limit treatment-related morbidity and mortality, and on developing strategies to improve the hematologic CR rate. To this end, we are currently exploring tandem HDM/SCT in AL amyloidosis. A role for non-myeloablative allogeneic transplantation may also be defined in the future.
In spite of promising results, high-dose chemotherapy and autologous stem cell transplant for AL amyloidosis is still a new therapy and should be carried out in the context of clinical trials. A crucial question is whether phase III randomized trials of high-dose melphalan and stem cell Bone Marrow Transplantation transplant vs cyclic oral melphalan with prednisone should be done. A review of Mayo Clinic data has indicated that selection bias probably accounts for at least some of the differences in outcome for patients treated with HDM/SCT when compared with historical controls treated with oral cyclic melphalan and prednisone. 18 In this review, it was noted that the subgroup of patients less than age 70, without cardiac involvement, renal failure, or significant liver disease had a median survival of 45.6 months when treated with oral melphalan and prednisone -a survival which was much better than that of all AL amyloidosis patients considered together. However, in our experience, patients without cardiac disease who underwent treatment with HDM/SCT, achieved a 4 year survival of 85% (Table 1) , and the median survival of this group has not been reached. We plan to carry out case-control studies to compare highdose chemotherapy and stem cell transplant to standarddose melphalan and prednisone to further address this question. However, we currently believe that given our phase II experience, it may prove difficult to design an ethical trial of HDM/SCT vs standard oral melphalan and prednisone. At the same time, we do not preclude the possibility that alternative protocols using dose-intensified chemotherapy with growth factor support alone without stem cell rescue, or using other therapeutic modalities, for patients ineligible for HDM/SCT, will deserve evaluation in randomized studies.
